Oncology
🇺🇸 FDA Page 10FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 109–120 of 246 articles
FDA's New AI Validation Framework in Oncology Drug Development
FDA Accelerated Approvals Oncology: 2026 Review of Benefit-Risk and Confirmatory Trials
FDA Accelerated Approval Pathway: Impact on Oncology Drug Development & Market Access 2026
FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
ASCO 2026: Key Oncology Data Readouts to Watch
ASCO 2026: Top Oncology Trials to Watch
Soligenix HyBryte Phase 3 FLASH2 Trial Shows Interim Results for Cutaneous T-Cell Lymphoma Treatment
Orca Bio's Orca-Q Receives FDA RMAT Designation for High-Risk Blood Cancers Treatment
Bispecific Antibody Therapies in RRMM: Teclistamab & Emerging Trends (FDA 2025)
Pharma Partnering US: Emergent, EvolveImmune Deals Emerge
Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
Jazz Pharmaceuticals' Ziihera Gets FDA Priority Review for First-Line HER2+ Cancer Treatment